The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

RSV vaccines could get broader CDC backing for adults aged 50-59 at risk after an endorsement from an agency's expert panel. Read more here.

GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware federal court. The deal blocks the parties from renewing their claims or ...

GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizer’s RSV vaccine, Abrysvo, which GSK claimed infringed on its own RSV shot, Arexvy.

(Reuters) -British pharmaceutical giant GlaxoSmithKline (GSK.L) and rival Pfizer (PFE) have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK ...

The recombinant vaccine extended dementia-free ... Shingrix sales for 2024 reached 3.36 billion pounds, down 2% (+1% at constant currency). Price Action: GSK stock is up 3.71% at $39.04 at the ...

(Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that alleged Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violated GSK's patent ...

GSK sued Pfizer in 2023, arguing that the New York-based company's vaccine infringed GSK patents ... Energycategory Oil prices slide 2% to nearly 4-year low as US trade conflict fuels recession ...

GSK will provide Innovax with the adjuvant need for a preclinical test of the vaccine which is based on a series of truncated S (spike) proteins from the novel coronavirus SARS-CoV-2 that causes ...